Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H

Autor: Gubens, Matthew A., Sequist, Lecia V., Stevenson, James P., Powell, Steven F., Villaruz, Liza C., Gadgeel, Shirish M., Langer, Corey J., Patnaik, Amita, Borghaei, Hossein, Jalal, Shadia I., Fiore, Joseph, Saraf, Sanatan, Raftopoulos, Harry, Gandhi, Leena

Publikováno v: In Lung Cancer April 2019 130:59-66

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

Autor: Langer, Corey J, Gadgeel, Shirish M, Borghaei, Hossein, Papadimitrakopoulou, Vassiliki A, Patnaik, Amita, Powell, Steven F, Gentzler, Ryan D, Martins, Renato G, Stevenson, James P, Jalal, Shadia I, Panwalkar, Amit, Yang, James Chih-Hsin, Gubens, Matthew, Sequist, Lecia V, Awad, Mark M, Fiore, Joseph, Ge, Yang, Raftopoulos, Harry, Gandhi, Leena

Publikováno v: In The Lancet Oncology November 2016 17(11):1497-1508

Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation

Autor: Yang, James Chih-Hsin, Gadgeel, Shirish M., Sequist, Lecia VanDam, Wu, Chien-Liang, Papadimitrakopoulou, Vassiliki A., Su, Wu-Chou, Fiore, Joseph, Saraf, Sanatan, Raftopoulos, Harry, Patnaik, Amita

Publikováno v: In Journal of Thoracic Oncology March 2019 14(3):553-559

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop

Autor: Bedognetti, Davide, Ceccarelli, Michele, Galluzzi, Lorenzo, Lu, Rongze, Palucka, Karolina, Samayoa, Josue, Spranger, Stefani, Warren, Sarah, Wong, Kwok-Kin, Ziv, Elad, Chowell, Diego, Coussens, Lisa M, De Carvalho, Daniel D, DeNardo, David G, Galon, Jérôme, Kaufman, Howard L, Kirchhoff, Tomas, Lotze, Michael T, Luke, Jason J, Minn, Andy J, Politi, Katerina, Shultz, Leonard D, Simon, Richard, Thórsson, Vésteinn, Weidhaas, Joanne B, Ascierto, Maria Libera, Ascierto, Paolo Antonio, Barnes, James M, Barsan, Valentin, Bommareddy, Praveen K, Bot, Adrian, Church, Sarah E, Ciliberto, Gennaro, De Maria, Andrea, Draganov, Dobrin, Ho, Winson S, McGee, Heather M, Monette, Anne, Murphy, Joseph F, Nisticò, Paola, Park, Wungki, Patel, Maulik, Quigley, Michael, Radvanyi, Laszlo, Raftopoulos, Harry, Rudqvist, Nils-Petter, Snyder, Alexandra, Sweis, Randy F, Valpione, Sara, Zappasodi, Roberta, Butterfield, Lisa H, Disis, Mary L, Fox, Bernard A, Cesano, Alessandra, Marincola, Francesco M, Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups

Publikováno v: Journal for immunotherapy of cancer, vol 7, iss 1
Journal for Immunotherapy of Cancer
Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups 2019, ' Toward a comprehensive view of cancer immune responsiveness : a synopsis from the SITC workshop ', Journal for ImmunoTherapy of Cancer, vol. 7, no. 1, pp. 131 . https://doi.org/10.1186/s40425-019-0602-4
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-23 (2019)

Tumor immunology has changed the landscape of cancer treatment. Yet, not all patients benefit as cancer immune responsiveness (CIR) remains a limitation in a considerable proportion of cases. The multifactorial determinants of CIR include the genetic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::182efc645395a8037ba7d37845a167b5
https://doi.org/10.1186/s40425-019-0602-4

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.